Cambridge Healthtech Institute's Fourth Annual

Engineering Next-Generation Cancer Immunotherapies

( 次世代がん免疫療法の開発 )

New Protein Engineering Science and Technology to Support the Development of Novel Immunotherapeutics and Treatment Combinations

2018年1月8日 - 9日



Final Agenda


7:30 am Registration and Morning Coffee

Antibody Engineering Challenges for Immunotherapeutics

9:00 Welcome by Conference Organizer

Kent Simmons, Senior Conference Director, Cambridge Healthtech Institute

9:05 Chairperson's Opening Remarks

Dimiter S. Dimitrov, Ph.D., Senior Investigator, Protein Interactions Section, Cancer and Inflammation Program, National Cancer Institute, NIH


9:10 Evolution and Advancements in Cancer Immunotherapy

Partha_ChowdhuryPartha Chowdhury, Ph.D., Senior Director and Head, Antibody Discovery, Sanofi Genzyme

Cancer is an immunological disease characterized by hijacking and evasion of the natural immune response of the host. Although the idea to exploit the host's immune response to fight against cancer is decades old, clinical success of immunotherapy is a relatively new achievement. This talk will focus on the various strategies used to manipulate a multitude of factors that underlies the phenomenon of immunotherapy, including recent advancements on new targets and approaches to enhance the therapeutic efficacy of novel biological drugs.

9:50 Optimization of Immune Regulatory Antibodies for Depletion of Regulatory T Cells

Frederick_Arce-VargasFrederick Arce-Vargas, M.D., Ph.D., Research Associate, University College London Cancer Institute, United Kingdom

Modulation of the anti-tumor immune response with antibodies targeting co-inhibitory and co-stimulatory molecules is a promising strategy in cancer therapy. In some cases, the effectiveness of these antibodies is not limited to receptor activation or blockade and also relies on depletion of Tregs. Characterizing the expression density of these targets in different T cell compartments and the myeloid cells involved in Treg depletion is paramount for the design of next generation immune-modulatory antibodies.

10:20 Networking Coffee Break

10:45 The Impact of mAb Format in Targeting the Tumor Microenvironment

Stephen_BeersStephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton, United Kingdom

Monoclonal antibodies (mAb) are transforming cancer therapy. Although the number of mAb reaching the clinic continues to rise rapidly, successful targets are scarce and new ones frequently fail. Understanding why promising pre-clinical candidates do not translate to humans is a critical question. Here we show how mAb format can be key to efficacy and that this could be particularly relevant when seeking new mAb to target the tumor microenvironment.

11:15 Novel Therapeutic Antibodies for Cancer Isolated from Single Human B Cells

Edward_PatzEdward F. Patz, Jr., M.D., Professor, Radiology, Pharmacology and Cancer Biology Duke University Medical Center

In an effort to develop novel therapeutic antibodies, we took cues from the native immune response in "exceptional outcomes" patients. We identified relevant tumor antigens by exploring the humoral response against the tumor, and then isolated and expressed DNA sequences from the relevant single B cells. A recombinant antibody was produced, and showed anti-tumor activity. This strategy represents an alternative paradigm in anti-cancer drug discovery.

11:45 Manipulation of Affinity Maturation and B Cell Subsets in vivo

Ali_ZarrinAli Zarrin, Ph.D., Senior Scientist, Immunology and Antibody Engineering, Genentech

B cells diversify their immunoglobulin genes to produce high affinity antibodies. Antigen specific B cells are selectively differentiated in the germinal centers to seed short- or long- lived plasma cells, a process known as affinity maturation. It is not clear how B cells commit to short or long-lived plasma cell fate. Our study provides insights on how this decision might be made during immune response and autoimmunity.

12:15 pm Sponsored Presentation (Opportunity Available)

12:45 Session Break

1:00 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

Immunotherapy Combinations

2:00 Chairperson's Remarks

Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton, United Kingdom

2:05 Update on Clinical Progress of Immunotherapy Combinations

Gregory Daniels, M.D., Ph.D., Professor, Medicine, Moores Cancer Center, University of California, San Diego

Tumors development occurs in the context of a functioning immune system with intrinsic and extrinsic growth pathways dynamically shaping a pro-tumor microenvironment. Tumor response to current therapies depend upon the quantitate and qualitative presence of the natural immune response. I will discuss examples of combination immune therapy in solid tumors that overcome the barriers in generating an anti-tumor response.

2:35 Rational Combination of Oncolytic Virus and Checkpoint Therapy

Jason DeVoss, Ph.D., Senior Scientist, Oncology, Amgen

3:05 Sponsored Presentation (Opportunity Available)

3:20 BuzZ Sessions with Refreshments

Join your peers and colleagues for interactive roundtable discussions.

Emerging Pathways and Targets for Cancer Immunotherapy

4:30 Epigenomic Mapping to Discover Novel Immunotherapy Targets

Pandurangan Vijayanand, M.D., Ph.D., Associate Professor, Vaccine Discovery, La Jolla Institute for Allergy and Immunology

5:00 The Importance of Fc Receptor Interactions for OX40 Agonists and Their Ability to Drive Tumor Ag-Specific T Cell Expansion

Andrew_WeinbergAndrew Weinberg, Ph.D., Judy Ann Hartmann Endowed Chair for Cancer Immunology Research, Robert W. Franz Cancer Research Center

OX40 agonists have been shown to increase T cell effector function, proliferation and survival. These T cell stimulating properties are important to enhance anti-tumor therapeutic efficacy. We have found that Fc receptor interactions are important for the agonist properties of these OX40 targeting Abs, which appear to be completely independent of Treg depletion. Recently we have found that OX40 agonists can expand tumor reactive T cells within the cancer microenvironment.

5:30 Targeted Mass Spectrometry for Cancer Antigen Discovery

Paul_ArmisteadPaul Armistead, M.D., Ph.D., Associate Professor, Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill

Mass spectrometry based identification of HLA-bound, cancer antigens is essential for many immunotherapeutic strategies; however, standard non-targeted methods are insensitive and inadequate for the discovery of previously undefined peptides (e.g., neoantigens). These problems can be overcome, however, by optimizing mass spectrometers for the targeted detection of specific antigens. Targeting approaches that we have adopted involve differential ion mobility spectrometry for target enrichment and parallel reaction monitoring for target confirmation.

6:00 - 7:15 Welcome Reception in the Exhibit Hall with Poster Viewing

7:15 Close of Day


8:00 am Registration and Morning Coffee

Novel Immunotherapies

8:30 Chairperson's Remarks

G. Jonah Rainey, Ph.D., Executive Director, Research, MabVax Therapeutics Holdings, Inc.

8:35 Efficacy of CAR-T Cells and Other Immunotherapies

Dimiter_DimitrovDimiter S. Dimitrov, Ph.D., Senior Investigator, Protein Interactions Section, Cancer and Inflammation Program, National Cancer Institute, NIH

Parameters that could affect efficacy of CAR-T cells and other immunotherapies including affinity, epitope location, surface expression and concentration of target cell surface associated antigen will be discussed as well as possible underlying mechanisms. Specific examples will be presented including an update on the high efficacy of the anti-CD22 CARs based on the scFv m971 as well as newly developed BiKEs targeting the HIV-1 envelope glycoprotein.

9:05 Neo-Antigen Targeting and Biomarkers in Cancer Immunotherapy

Laszlo_RadvanyiLaszlo Radvanyi, Ph.D., Senior Vice President, Senior Scientific Advisor, Immunology, Immuno-Oncology, EMD Serono R&D Institute (a business of Merck KGaA, Darmstadt, Germany)

This talk will discuss the emerging field of neo-antigen (mutanome) targeting. I will summarize current approaches used to deduce cancer neo-antigen epitopes and provide examples of how neo-antigens are being targeted in cancer immunotherapy clinical trials and the application of mutanome evaluation as a predictive biomarker. The talk also describes some conceptual obstacles being faced in the field and comment on the strategic position and future impact of neo-antigen targeting in the overall cancer immunotherapy landscape.

9:35 Sponsored Presentation (Opportunity Available)

9:50 Coffee Break in the Exhibit Hall with Poster Viewing

11:00 A New Immunomodulatory Strategy of Releasing Immunosuppression in the Tumor Microenvironment

Li_PengLi Peng, Ph.D., Vice President, Antibody Engineering and Protein Sciences, Palleon Pharmaceuticals

Cancer therapy has been revolutionized by inhibiting immune-checkpoints to harness the power of the immune system in fighting cancer. Immune-checkpoint inhibitors have proved to achieve a durable response in a subset of cancer patients. However, most patients are still resistant to these first generation I/O drugs. Enormous effort is pursued to identify new immunomodulatory strategies. We describe a novel approach of blocking an immunosuppression pathway involved in innate and adaptive response.

11:30 Achieving Broad Tumor Coverage by Targeting Cancer Carbohydrate Antigens: Lessons from the Clinic Accelerate Development of Additional Targets

Jonah_RaineyG. Jonah Rainey, Ph.D., Executive Director, Research, MabVax Therapeutics Holdings, Inc.

Glycans are promising therapeutic targets present on broad tumor types. We are clinically developing an anti-sialyl Lewis A (sLea) naked antibody (MVT-5873), immunoPET imaging agent (MVT-2163), and radioimmunoconjugate (MVT-1075). Here we describe a fully human antibody against another cancer glycan, Tn (GalNAc alpha-O-Ser/Thr), which shows minimal overlap with sLea by tumor microarray. We compare translational learnings from anti-sLea programs and describe how they have guided development of our anti-Tn effort.

12:00 pm Sponsored Presentation (Opportunity Available)

12:30 Session Break

12:45 Luncheon Presentation: Identification of Novel Receptor Targets and Specificity Screening of Biotherapeutics

Alex_KellyAlex Kelly, Business Development Manager, Retrogenix Limited

Human cell microarray screening enables the discovery of primary cell surface receptors and off-targets for a variety of biotherapeutic molecules, including peptides, antibodies and proteins, as well as CAR T and other cell therapies. Case studies will demonstrate the utility of the technology in identifying novel immunotherapy targets as well as in specificity screening for biotherapeutics to aid safety assessment and provide critical data to support IND submissions.

1:15 Close of Engineering Next-Generation Cancer Immunotherapies Conference

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。